NURS2132 Lecture Notes - Lecture 10: Insulin Glargine, Insulin Analog, Insulin Pump
Document Summary
Inhaled insulin is not approved for use in canada. Insulin delivered by basal-bolus injection therapy or continuous subcutaneous insulin infusion (csii, also called insulin pump therapy) as basal and bolus regimens are preferred. Insulin aspart, glulisine and lispro should be administered 0 to 15 minutes before the start of the meal while short-acting regular insulin should be administered 30 to. 45 minutes before the start of the meal. Faster-acting insulin aspart may be administered at the start of the meal or, when necessary, up to 20 minutes after the start of the meal. Hypogylcemia and insulin therapy: hypoglycemia is the most common adverse effect of insulin therapy in people with type. These effects on bg levels can be modified by altering diet, insulin, and the type and timing of physical activity. In contrast, high-intensity exercise raises bg levels during and immediately after the event but may result in hypoglycemia hours later.
